Much recent effort has gone into HD protein-lowering approaches, but we hypothesize that methods that target the downstream aggregation process may be a valuable complement, also given recent challenges in clinical tests of Htt lowering in patients35. The gene discussed is HTT; the disease is Huntington disease.